|
End-of-day quote
Taipei Exchange
2026-10-12
|
5-day change | 1st Jan Change | ||
| 171.50 TWD | -2.00% |
|
-5.51% | +331.99% |
| 08-14 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| 04-28 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Market Cap | 142B 4.45B 3.98B 3.71B 3.37B 6.35B 425B 6.39B 44.63B 17.47B 220B 16.72B 16.35B 706B | P/E 2024 |
-14.5x | P/E 2025 | -23.9x |
|---|---|---|---|---|---|
| Enterprise Value | 126B 3.94B 3.53B 3.29B 2.98B 5.63B 377B 5.66B 39.53B 15.47B 194B 14.8B 14.48B 626B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
100% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -2.00% | ||
| 1 week | -5.51% | ||
| Current month | -9.97% | ||
| 1 month | +4.89% | ||
| 3 months | +180.23% | ||
| 6 months | +338.06% | ||
| Current year | +331.99% |
| 1 week | 169 |  | 185 |
| 1 month | 155 | | 207 |
| Current year | 33.1 | | 207 |
| 1 year | 20.4 | | 207 |
| 3 years | 7 | | 207 |
| 5 years | 7 | | 207 |
| 10 years | 2.7 | | 207 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cheng Chi Wang
CEO | Chief Executive Officer | - | 2016-05-31 |
Wan Shan Chen
DFI | Director of Finance/CFO | 40 | 2022-07-24 |
Hung Wei Chen
COO | Chief Operating Officer | 45 | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Yue Hsin Lin
CHM | Chairman | 48 | 2016-10-12 |
Cheng Chi Wang
BRD | Director/Board Member | - | 2024-06-26 |
Hui Chun Wang
BRD | Director/Board Member | 80 | 2018-09-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.00% | -5.51% | +677.78% | +1,473.39% | 4.54B | |
| +0.28% | +3.46% | +44.33% | +93.71% | 1,051B | |
| +0.88% | +4.27% | +38.15% | +68.70% | 630B | |
| +1.68% | +5.78% | +22.07% | +89.56% | 489B | |
| -0.10% | +4.24% | +69.72% | +40.41% | 359B | |
| +0.61% | +4.14% | +24.05% | +41.70% | 344B | |
| +0.72% | +3.11% | +14.29% | +33.76% | 272B | |
| +0.23% | +1.31% | -5.91% | +9.89% | 246B | |
| +0.65% | +3.62% | +42.81% | +46.50% | 224B | |
| -0.49% | +4.01% | +27.26% | +95.97% | 187B | |
| Average | +0.27% | +2.57% | +95.45% | +199.36% | 380.82B | |
| Weighted average by Cap. | +0.64% | +2.93% | +35.44% | +68.58% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | -744M -23.29M -20.85M -19.44M -17.63M -33.25M -2.23B -33.46M -234M -91.44M -1.15B -87.49M -85.56M -3.7B | -1.36B -42.65M -38.18M -35.59M -32.28M -60.89M -4.08B -61.27M -428M -167M -2.1B -160M -157M -6.77B |
| Net Debt | -5.17B -162M -145M -135M -123M -231M -15.48B -233M -1.62B -636M -7.99B -608M -595M -25.71B | -16.27B -509M -456M -425M -385M -727M -48.67B -731M -5.11B -2B -25.12B -1.91B -1.87B -80.83B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-11 | NT$171.50 | -2.00% | 3,796,218 |
| 26-10-08 | NT$175.00 | +1.16% | 2,884,939 |
| 26-10-07 | NT$173.00 | -3.89% | 4,844,408 |
| 26-10-06 | NT$180.00 | +4.96% | 4,859,908 |
| 26-10-05 | NT$171.50 | -5.51% | 11,835,303 |
- Stock Market
- Stocks
- 6696 Stock
Select your edition
All financial news and data tailored to specific country editions
